ArticleEmerging infectious diseases2016
Effectiveness of Meningococcal B Vaccine against Endemic Hypervirulent Neisseria meningitidis W Strain, England.
Article in Emerging infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Cost-Effectiveness of Routine Infant Meningococcal B Vaccination in the Netherlands.Infectious diseases and therapy · 2026Article
- Safety and immunogenicity of concomitant quadrivalent meningococcus ACYW-TT and meningococcus group B vaccines.NPJ vaccines · 2026Article
- Meningococcal Outbreaks in Tertiary Education Settings in the United Kingdom: Lessons from the 2026 Kent Cluster for Surveillance, Vaccination Policy, and Institutional Preparedness in Sub-Saharan Africa-A Narrative Review.Infectious disease reports · 2026Review
- Genomic characterization of Neisseria meningitidis from urethritis in a sentinel surveillance hospital, China.BMC microbiology · 2026Article
- Bacterial Extracellular Vesicles and Antimicrobial Peptides: A Synergistic Approach to Overcome Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2025Review
- Factor H binding protein (FHbp): An evaluation of genotypic diversity acrossHuman vaccines & immunotherapeutics · 2024Review
- Lifecycle model-based evaluation of infant 4CMenB vaccination in the UK.The European journal of health economics : HEPAC : health economics in prevention and care · 2024Article
- Bactericidal killing of meningococcal W strains isolated in Argentina by the sera of adolescents and infants immunized with 4-component meningococcal serogroup B vaccine (4CMenB).Human vaccines & immunotherapeutics · 2023Article
- Epidemiology, clinical features and outcome of adults with meningococcal meningitis: a 15-year prospective nationwide cohort study.The Lancet regional health. Europe · 2023Article
- Product review on the IMD serogroup B vaccine Bexsero®.Human vaccines & immunotherapeutics · 2022Article
- Review
- Cross-reactivity of 4CMenB vaccine-induced antibodies against meningococci belonging to non-B serogroups in Italy.Human vaccines & immunotherapeutics · 2021Article
- First immunogenicity data for the UK serogroup B meningococcal vaccination schedule in infants.The Lancet. Infectious diseases · 2021Article
- Molecular diagnostic assays for the detection of common bacterial meningitis pathogens: A narrative review.EBioMedicine · 2021Review
- 4CMenB Immunization Induces Serum Bactericidal Antibodies Against Non-Serogroup B Meningococcal Strains in Adolescents.Infectious diseases and therapy · 2021Article
- Article
- Vaccines against Meningococcal Diseases.Microorganisms · 2020Review
- Transmissibility and pathogenicity of the emerging meningococcal serogroup W sequence type-11 complex South American strain: a mathematical modeling study.BMC medicine · 2020Article
- Epidemiologic Trends, Global Shifts in Meningococcal Vaccination Guidelines, and Data Supporting the Use of MenACWY-TT Vaccine: A Review.Infectious diseases and therapy · 2019Review
- Meningococcal vaccines in Australia: a 2019 update.Australian prescriber · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serum samples from children immunized with a meningococcal serogroup B vaccine demonstrated potent serum bactericidal antibody activity against the hypervirulent Neisseria meningitidis serogroup W strain circulating in England. The recent introduction of this vaccine into the United Kingdom national immunization program should also help protect infants against this endemic strain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.